文献速递前列腺癌

美国前列腺癌根治术后高剂量与极高剂量放疗的使用趋势

Use of high and very high dose radiotherapy after radical prostatectomy for prostate cancer in the United States.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-08-07

该研究基于美国国家癌症数据库(NCDB)2003-2012年数据,分析pT2-3N0M0前列腺癌患者R0-1切除后接受术后放疗(PORT)的剂量使用情况。结果显示高剂量PORT使用率从29.9%增至63.5%,极高剂量PORT从4.5%增至10.8%,两者均翻倍且趋势显著(调整p<0.01)。社区中心患者接受高剂量PORT的可能性低于学术或综合中心。结论认为在缺乏随机研究证据的情况下剂量强化实践增加,可能使患者暴露于额外毒性而无肿瘤控制获益。

要点

  • 2003-2012年间高剂量和极高剂量PORT使用率均翻倍,调整p<0.01。
  • 社区中心患者接受高剂量PORT的可能性低于学术或综合中心(p<0.01)。
  • 该剂量强化发生在无随机研究证据的时期,可能增加毒性而无获益。

核心结论

  • 2003-2012年间高剂量和极高剂量PORT使用率均翻倍,但缺乏随机研究证据支持剂量强化。
  • 剂量强化实践可能使患者暴露于额外毒性而无肿瘤控制获益。
  • 利用癌症登记系统监测放疗剂量模式是可行的。

研究设计与样本

  • 基于美国国家癌症数据库(NCDB)2003-2012年的回顾性分析。
  • 纳入pT2-3、N0、M0前列腺癌患者,均接受R0-1切除后的PORT。
  • 高剂量定义为>66.60 cGy,极高剂量定义为>70.20 cGy。
  • 采用回归分析评估治疗年份与高/极高剂量PORT使用的关联。

主要发现

  • 两种剂量趋势的调整p值均<0.01。
  • 社区中心患者接受高剂量PORT的可能性低于学术中心(p<0.01)和综合中心(p<0.01)。
  • 若NCDB网络前瞻性监测PORT剂量,显著增加最早可在2004年及之后每一年被检测到。

关键数值与推荐

  • 高剂量PORT定义为>66.60 cGy。
  • 极高剂量PORT定义为>70.20 cGy。

临床怎么用

  • 临床医生应认识到前列腺癌根治术后剂量强化缺乏随机证据支持。
  • 应关注剂量强化可能带来的额外毒性而无肿瘤控制获益。
  • 可利用癌症登记系统监测放疗剂量模式变化。

局限性

  • 研究为回顾性分析,非随机对照试验。
  • 未报告毒性或肿瘤控制结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cost-benefit tradeoff of radiation dose-intensification for prostate cancer in the post-prostatectomy setting is difficult to predict and is ideally studied in randomized trials. The purpose of this study was to assess the use of dose-escalated post-operative radiation (PORT) for prostate cancer in the United States, during a period in which there were no published level 1 studies on dose-escalation. METHODS: We performed analyses on pT2-3, N0, M0 prostate cancer patients who received PORT after an R0-1 resection within the National Cancer Data Base (NCDB), 2003-2012. We classified patients according to the use of high dose (>66.60 cGy) and very high dose (>70.20 cGy) radiation. We used regression analysis to assess the association of year of treatment with use of high and very high dose PORT. To demonstrate the potential of a registry-based network like the NCDB to prospectively monitor changes in radiation dosing patterns, we determined the year in which a significant change in dose could have been first detected had dose been actively monitored. RESULTS: Between 2003 and 2012, the use of high dose PORT increased from 29.9% CI (26.7-33.1) to 63.5% CI (60.6-66.5) and very high dose PORT from 4.5% CI (3.1-5.9) to 10.8% CI (8.9-12.6) (adjusted p < 0.01, for both trends). Patients diagnosed at community centers were less likely to be treated with high dose PORT compared to those at academic or comprehensive centers (p < 0.01 for both comparisons). Had the NCDB network been prospectively monitoring PORT dose, significant increases in dose would have been detected as early as 2004 and after every year of the study period. CONCLUSIONS: The use of both high dose and very high dose PORT increased two-fold from 2003 to 2012 in the absence of randomized studies. This change in practice may be exposing patients to excess toxicity without cancer control benefits. Monitoring dosing patterns using cancer registries is feasible.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Alexidis P, Guo W, Bekelman JE, et al. Use of high and very high dose radiotherapy after radical prostatectomy for prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2018. PMID: 30087427. doi:10.1038/s41391-018-0066-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。